July 20, 2018 5:09pm

Gene editing companies are feeling the low digit trades and with only 1 to the upside (EDIT +$0.12)

An unanswered question is, “what happens to distant metastases even if CRISP rehoming cells successfully attack the original tumor?”

 

Would you bet your life and your current portfolio on a mouse model; it’s always a game of “truth or consequences”!

 

Pre-open indications: 6 hits and 3 miss

 

I say today what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  Want to know WHY, WHAT and HOW, subscribe!

 


Henry’omics:

 

For the week, the S&P 500 and NASDAQ closed slightly lower while the Dow rose 0.1% to post its first three-week winning streak since January.

While the sector closed with 3 negative and two positive closes for the week!

And volume continues LOW with a few exceptions (BTX to the upside (+$0.01), VYGR (+$0.36) and XON (+$0.08); the downsized volume was relegated to BMRN (-$0.97) and MDXG (-$0.28).

TGIF … mixed beverages await me!

 

Let the numbers, the count and daily metrics speak ...

The advance/decline line scenario of 45 covered companies:   

  • The open was positive with an A/DL of 25/15 and 5 flats;
  • The mid-day stayed positive with an A/DL of 25/16 and 4 flats;
  • The close was negative with an A/DL of 15/24 and 5 flats;

 

Pre-open indications: 6 hit and 3 miss

  • Crispr (CRSP) closed down -$0.04 – hit;
  • Editas (EDIT) closed up +$0.12 – miss;
  • Intellia (NTLA) closed down -$0.01 – hit;
  • BioLife Solutions (BLFS) closed up +$0.87 – miss;
  • Biostage (BSTG) closed flat – hit;
  • Athersys (ATHX) closed up +$0.00 – hit;
  • Asterias Biotherapeutics (NYSEMKT: AST) closed up +$0.05 – hit;
  • Fate Therapeutics (FATE) closed down -$0.26 – miss; 
  • Verastem Oncology (VSTM) closed up +$0.18 – hit;

 

From the pre-open newsletter titled, “speculation is in vogue, when isn’t it? In the daily churn of the sector, one has to call it as one sees them; as algorithms “rule” and ETF weighting’s balance or are in-balanced as dark pools get more disadvantaging.   It’s still a question of what’s in an investor’s “mind’s eye”.  Are we depending on past pricing or altered value stories?”

I also stated, “Or should we just wait for re-incarnation of the “Gong Show”?”

 

It remains to be seen if CRISPR works in humans; maybe we will see in ten maybe twenty years – can your portfolio withstand that assault? It is a short and near-term trading play!!

Friday: follow the bouncing share pricing, a session of speculation to the downside: CRISPR Therapeutics (CRSP -$0.04 or +0.07%); Editas Medicine (EDIT +$0.12 or +0.33%) and Intellia Therapeutics (NTLA -$0.01 or -0.03%) …

Thursday for gene editing companies was a day of “rhyme or reason” with the oversold getting yet again ready to be overbought again as trading speciation controlled the session: CRISPR Therapeutics (CRSP +$0.21 or +0.36%) stayed down for the count; Editas Medicine (EDIT +$0.75 or +2.12%) and Intellia Therapeutics (NTLA +$0.63 or +2.03%) … flew close to the flatlands to not melt their upside (the Icarus story) after …

Wednesday, what has speculation born: gene editing stocks dumped: Editas Medicine (EDIT -$1.08 or -2.96%), CRISPR Therapeutics (CRSP -$3.48 or -5.61%) and Intellia Therapeutics (NTLA -$0.36 or -1.15%) …

Tuesday, gene editing stocks high jumped in response to their dramatic decline: Editas Medicine (EDIT +$1.26 or +3.58%) with 606.79 K shares traded, CRISPR Therapeutics (CRSP +$1.95 or +3.25%) with 787.9 K shares traded and Intellia Therapeutics (NTLA +$2.00 or +6.81%) with 637.4 K shares traded …

Monday, gene editing stocks dropped like stones in a lake: Editas Medicine (EDIT -$2.70 or -7.21%) with 1.52 M shares traded <3 month average = 1.52 M, CRISPR Therapeutics AG (CRSP -$5.65 or -8.60%) with 2.83 M shares traded <3 month average = 1.55 M shares> and Intellia Therapeutics (NTLA -$3.24 or -9.94%) with 1.33 m shares traded <3 month average = 928.4 K shares> …

 

Of the 45 companies covered on Thursday; 24 downside equities finished in a range of -$0.00 or -0.94% (KOOL) to -$2.75 (RGNX) while the 15 upside equities oscillated from +$0.0 (OSIR) to $1.40 (BLUE) with 6 flat closes.

 

MY working trend (5 largest) lines:

… The greatest volume to the downside:  XON, VYGR, VSTM, VCEL and SGMO

… Upside volume was weighted to:  SLDB, SAGE, RGNX, RARE and QURE

… Biggest $ downside: RGNX (-$2.75), QURE (-$1.51), SLDB (-$1.00), RARE (-$1.00) and BMRN (-$0.97)

 … Best moves to the $ upside: BLUE (+$1.40), BLFS (+$0.87), BOLD (+$0.78), IONS (+$0.66) and VYGR (+$0.36)

… Flats:  ATHX, BSTG, PSTI, BCLI, RENE.L and STML

 

The weekly count - decliners versus gainers – looks at the view from different angles:

……. look at the differences in decliners:

  • Friday’s decliners ranged from -0.03% <NTLA (-$0.01 > to -6.97% < MDXG -$0.28> in 24 equities;
  • Thursday’s decliners ranged from -0.24% < CRSP -$0.14> to -3.83% <ONCE -$3.27 > in 14 equities;
  • Wednesday’s decliners ranged from -0.13% <RGNX -$0.10 > to -8.59% <VYGR -$1.71 > in 30 equities;
  • Tuesday’s decliners ranged from -11% < KOOL -$0.0529> to -0.36% <IONS -$0.16 > in 13 equities;
  • Monday’s decliners ranged from -0.25% <RARE -$0.21> to -12.85% <BSTG -$0.51> in 32 equities;
  • Last Friday’s decliners ranged from -0.39% <BOLD -$0.15 > to -10.34% <VCEL -$1.05 > in 17 equities;

Versus

… Look at the percentage’s (%) and spreads …

  • Friday’s gainers ranged from +0.10% <OSIR +$0.01 > to +4.12% <BLFS +$0.87 > in 15 equities;
  • Thursday’s gainers ranged from +0.18% <BMRN +$0.18 > to +21.68% <BSTG +$0.70 > in 30 equities;
  • Wednesday’s gainers ranged from +0.14% <KOOL+$0.0006> to +4.13% <BTX +$0.095 > in 13 equities;
  • Tuesday’s gainers ranged from +0.36% < SAGE +$0.61> to +12.69% < MESO +$0.76> in 29 equities;
  • Monday’s gainers ranged from +0.19% <SAGE +$0.32 > to +5.99% <KOOL +$0.027 > in 10 equities;
  • Last Friday’s gainers ranged from +0.07% < CLLS +$0.02> to +13.19% <CLBS +$0.72 > in 25 equities;

 

Daily analytics and metrics:

  • The Dow fell just 6.38 points to 25,058.12,
  • The S&P 500 slipped 0.1% to 2,801.83,
  • The NASDAQ declined 0.1% to close at 7,820.20.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market,

  • Friday traded at 12.83, down -0.31%
  • Thursday traded at 12.87, up +6.36%
  • Wednesday traded at 11.94, down -1%
  • Tuesday traded at 12.66, down -6%
  • Monday traded at 12.83, up +5.34%
  • Last Friday traded at 12.18, down -3.18%

 

The iShares Russell 2000 (IWM) closed:

  • Friday was down -0.42%;
  • Thursday was up +0.68%;
  • Wednesday was up +0.28%;
  • Tuesday was up +0.43%;
  • Monday was down -0.40%;
  • Last Friday was down -0.26%;

 

The iShares NASDAQ Biotechnology (IBB) closed:

  • Friday was down -0.08%
  • Thursday was up +0.10%
  • Wednesday was down -0.09%
  • Tuesday was up +0.75%
  • Monday was down -0.73%
  • Last Friday was up +0.17%

 

JULY sessions:

Friday closed NEGATIVE with 24 decliners, 15 advancers and 5 flats;

Thursday closed POSITIVE with 14 decliners, 28 advancers and 2 flats;

Wednesday closed NEGATIVE with 30 decliners, 13 advancers and 2 flat;

Tuesday closed POSITIVE with 13 decliners, 29 advancers and 3 flat;

Monday (7/16) closed NEGATIVE with 32 decliners, 10 advancers and 3 flat;

Friday closed POSITIVE with 17 decliners, 25 advancers and 3 flat;

Thursday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Wednesday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Tuesday closed NEGATIVE with 29 decliners, 15 advancers and 1 flat;

Monday (7/9) closed POSITIVE with 18 decliners, 22 advancers and 5 flat;

Friday closed POSITIVE with 8 decliners, 35 advancers and 2 flat;

Thursday closed POSITIVE with 18 decliners, 23 advancers and 4 flat;

Wednesday (7/4) was a holiday;

Tuesday closed POSITIVE with 9 decliners, 33 advancers and 3 flat;

Monday (7/2) closed POSITIVE with 15 decliners, 27 advancers and 3 flat;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.